🟢 Definium Therapeutics is trading 4.4% up today on technical rebound after sector weakness

Definium Therapeutics is trading 4.4% up at $45.55 as shares rebound from Monday’s technical pullback and broader biotech sector weakness.

• The stock is currently stabilizing following sharp gains driven by positive Phase 3 Emerge trial data for DT120 in major depressive disorder.
• Price action remains closely tied to broader biotech sentiment as there are no new company-specific announcements today.